Novo Nordisk Shares Plummet After Weight Loss Drug Trial Results Disappoint

Novo Nordisk, the Danish pharmaceutical giant renowned for its obesity treatments Wegovy and Ozempic, experienced a significant 16% drop in its share price on Monday, February 10, 2026, following the release of disappointing trial data for a new weight loss drug. This decline comes as the company faces increasing competition from Eli Lilly in the rapidly expanding weight loss market.

Competition Heats Up in the Obesity Drug Market

Novo Nordisk revolutionized obesity treatment with drugs like Ozempic and Wegovy, becoming the most valuable European company in 2023. However, the company has recently encountered challenges from competing drugs developed by Eli Lilly. The recent stock price drop was directly triggered by investor reaction to trial results indicating that the average weight loss achieved with Novo Nordisk’s new drug was less effective than that of comparable treatments from Eli Lilly.

Recent Financial Adjustments and Restructuring

Over the past year, Novo Nordisk has revised its profit forecasts multiple times. In September 2025, the company announced plans to reduce its global workforce by 9,000 employees, representing approximately 11% of its total workforce, including 5,000 positions in Denmark.

Wegovy Availability and Cost

Wegovy is now available as a once-daily pill, as well as an injection, and is the only semaglutide tablet FDA-approved for weight loss in adults. NovoCare offers savings and support resources, with potential savings of up to $100 per month, though government beneficiaries are excluded. More information on Wegovy cost and coverage is available on the Wegovy website.

Legal Action Against Counterfeit Drugs

Novo Nordisk is actively protecting its products and patients by taking legal action against companies selling counterfeit versions of Wegovy and Ozempic, such as Hims & Hers. The company announced this legal action on February 9, 2026.

Looking Ahead

Novo Nordisk faces a critical period as it navigates increased competition and adjusts its strategies in the evolving obesity treatment market. The company’s ability to innovate and maintain its market position will be closely watched by investors and the healthcare industry alike.